190 related articles for article (PubMed ID: 34911833)
21. Extracellular Vesicles from
Janpipatkul K; Panvongsa W; Worakitchanon W; Reungwetwattana T; Chairoungdua A
Anticancer Res; 2022 Aug; 42(8):3835-3844. PubMed ID: 35896267
[TBL] [Abstract][Full Text] [Related]
22. Let-7c regulated epithelial-mesenchymal transition leads to osimertinib resistance in NSCLC cells with EGFR T790M mutations.
Li XF; Shen WZ; Jin X; Ren P; Zhang J
Sci Rep; 2020 Jul; 10(1):11236. PubMed ID: 32641854
[TBL] [Abstract][Full Text] [Related]
23. [The role and mechanism of 2-deoxyglucose in reversing osimertinib-acquired resistance of non-small cell lung cancer cell line].
Hao S; Lu CH; Lin CC; Chen HY; Li L; Wang YB; Feng MX; He Y
Zhonghua Jie He He Hu Xi Za Zhi; 2019 Mar; 42(3):198-205. PubMed ID: 30845397
[No Abstract] [Full Text] [Related]
24. Overcoming acquired resistance of gefitinib in lung cancer cells without T790M by AZD9291 or Twist1 knockdown in vitro and in vivo.
Liu Z; Gao W
Arch Toxicol; 2019 Jun; 93(6):1555-1571. PubMed ID: 30993382
[TBL] [Abstract][Full Text] [Related]
25. Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI.
Weng CH; Chen LY; Lin YC; Shih JY; Lin YC; Tseng RY; Chiu AC; Yeh YH; Liu C; Lin YT; Fang JM; Chen CC
Oncogene; 2019 Jan; 38(4):455-468. PubMed ID: 30111817
[TBL] [Abstract][Full Text] [Related]
26. Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer.
Galvani E; Giovannetti E; Saccani F; Cavazzoni A; Leon LG; Dekker H; Alfieri R; Carmi C; Mor M; Ardizzoni A; Petronini PG; Peters GJ
Neoplasia; 2013 Jan; 15(1):61-72. PubMed ID: 23359111
[TBL] [Abstract][Full Text] [Related]
27. Experimental study of EGFR-TKI aumolertinib combined with ionizing radiation in EGFR mutated NSCLC brain metastases tumor.
Zhang Y; Li Y; Han Y; Li M; Li X; Fan F; Liu H; Li S
Eur J Pharmacol; 2023 Apr; 945():175571. PubMed ID: 36804545
[TBL] [Abstract][Full Text] [Related]
28. Targeting the EMT transcription factor Snail overcomes resistance to osimertinib in EGFR-mutant non-small cell lung cancer.
Qin Q; Li X; Liang X; Zeng L; Wang J; Sun L; Zhong D
Thorac Cancer; 2021 Jun; 12(11):1708-1715. PubMed ID: 33943009
[TBL] [Abstract][Full Text] [Related]
29. Ursolic acid promotes apoptosis and mediates transcriptional suppression of CT45A2 gene expression in non-small-cell lung carcinoma harbouring EGFR T790M mutations.
Yang K; Chen Y; Zhou J; Ma L; Shan Y; Cheng X; Wang Y; Zhang Z; Ji X; Chen L; Dai H; Zhu B; Li C; Tao Z; Hu X; Yin W
Br J Pharmacol; 2019 Dec; 176(24):4609-4624. PubMed ID: 31322286
[TBL] [Abstract][Full Text] [Related]
30. Suberoylanilide hydroxamic acid overcomes erlotinib-acquired resistance via phosphatase and tensin homolog deleted on chromosome 10-mediated apoptosis in non-small cell lung cancer.
Wu PF; Gao WW; Sun CL; Ma T; Hao JQ
Chin Med J (Engl); 2020 Jun; 133(11):1304-1311. PubMed ID: 32452893
[TBL] [Abstract][Full Text] [Related]
31. The third-generation EGFR inhibitor almonertinib (HS-10296) resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs.
Wu CP; Hung TH; Lusvarghi S; Chu YH; Hsiao SH; Huang YH; Chang YT; Ambudkar SV
Biochem Pharmacol; 2021 Jun; 188():114516. PubMed ID: 33713643
[TBL] [Abstract][Full Text] [Related]
32. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.
Shi P; Oh YT; Zhang G; Yao W; Yue P; Li Y; Kanteti R; Riehm J; Salgia R; Owonikoko TK; Ramalingam SS; Chen M; Sun SY
Cancer Lett; 2016 Oct; 380(2):494-504. PubMed ID: 27450722
[TBL] [Abstract][Full Text] [Related]
33. The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer.
Zhang Y; Zeng Y; Liu T; Du W; Zhu J; Liu Z; Huang JA
Respir Res; 2019 Jul; 20(1):164. PubMed ID: 31331328
[TBL] [Abstract][Full Text] [Related]
34. ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.
Li Y; Zang H; Qian G; Owonikoko TK; Ramalingam SR; Sun SY
Cancer; 2020 Mar; 126(6):1339-1350. PubMed ID: 31821539
[TBL] [Abstract][Full Text] [Related]
35. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
[TBL] [Abstract][Full Text] [Related]
36. Melatonin sensitizes H1975 non-small-cell lung cancer cells harboring a T790M-targeted epidermal growth factor receptor mutation to the tyrosine kinase inhibitor gefitinib.
Yun M; Kim EO; Lee D; Kim JH; Kim J; Lee H; Lee J; Kim SH
Cell Physiol Biochem; 2014; 34(3):865-72. PubMed ID: 25199820
[TBL] [Abstract][Full Text] [Related]
37. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
[TBL] [Abstract][Full Text] [Related]
38. Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial.
Yang JC; Camidge DR; Yang CT; Zhou J; Guo R; Chiu CH; Chang GC; Shiah HS; Chen Y; Wang CC; Berz D; Su WC; Yang N; Wang Z; Fang J; Chen J; Nikolinakos P; Lu Y; Pan H; Maniam A; Bazhenova L; Shirai K; Jahanzeb M; Willis M; Masood N; Chowhan N; Hsia TC; Jian H; Lu S
J Thorac Oncol; 2020 Dec; 15(12):1907-1918. PubMed ID: 32916310
[TBL] [Abstract][Full Text] [Related]
39. Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance.
Zhang T; Qu R; Chan S; Lai M; Tong L; Feng F; Chen H; Song T; Song P; Bai G; Liu Y; Wang Y; Li Y; Su Y; Shen Y; Sun Y; Chen Y; Geng M; Ding K; Ding J; Xie H
Mol Cancer; 2020 May; 19(1):90. PubMed ID: 32404161
[TBL] [Abstract][Full Text] [Related]
40. Effect of vitamin D on malignant behavior of non-small cell lung cancer cells.
Songyang Y; Song T; Shi Z; Li W; Yang S; Li D
Gene; 2021 Feb; 768():145309. PubMed ID: 33197518
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
